Synthetic Psychedelics 101: LSD, MDMA, Research Chemicals & Why Testing Matters

A clear guide to synthetic psychedelics — LSD, MDMA, 2C-B, ketamine, research chemicals, and the critical difference between tested and untested substances. (2026 Update)

When most people think about psychedelics, they picture plants — magic mushrooms, peyote cacti, ayahuasca vines. However, a large portion of the psychedelic landscape is synthetic: substances created in laboratories, often designed to mimic or improve upon natural compounds.

Synthetic psychedelics have shaped both the history and the future of psychedelic science. LSD launched the modern psychedelic era — and it is synthetic. MDMA is transforming PTSD treatment — also synthetic. Ketamine is already legally treating depression in clinics worldwide. All synthetic.

However, the word "synthetic" also covers a far darker territory. Today, hundreds of untested research chemicals flood the grey market every year. Understanding the critical difference between well-studied synthetic psychedelics and untested novel substances could save your life.

What Makes a Psychedelic "Synthetic"?

The term "synthetic" simply means that a substance is made through chemical synthesis in a laboratory. It is not extracted directly from a plant or fungus. However, the line is not always sharp. LSD derives from ergotamine, which occurs naturally in the ergot fungus. 5-MeO-DMT exists in toad venom but can also be synthesised.

In practice, "synthetic psychedelics" usually distinguishes substances like LSD and MDMA — where lab synthesis is the primary route — from substances like psilocybin truffles or ayahuasca, where the compound is consumed in its natural form.

Shulgin's Legacy: How Careful Science Should Work

No conversation about synthetic psychedelics is complete without Alexander Shulgin. Often called "the godfather of psychedelics," Shulgin synthesised and personally tested over 200 psychoactive compounds across his career. His two landmark books — PiHKAL (1991) and TiHKAL (1997) — documented every substance with full synthesis instructions, precise dosing, and detailed experience reports.

Shulgin's methodology was rigorous and systematic. He always started by taking a tiny dose himself. Then he gradually increased until he noticed an effect. Next, his wife Ann would try a comparable dose. Only then would his research group of eight to ten trusted friends test the substance. Each person reported their experience using the Shulgin Rating Scale — a standardised system ranging from minus (no effect) to four plus signs (transcendental).

Was this risky? Absolutely. Shulgin was essentially a human guinea pig. However, his approach had structure, documentation, and accountability. Every substance was catalogued with exact doses, onset times, duration, and subjective effects. The data from his group experiments remains foundational to psychedelic pharmacology today.

LSD: The Compound That Started It All

LSD (lysergic acid diethylamide) is the archetypal synthetic psychedelic. Swiss chemist Albert Hofmann first synthesised it in 1938 at Sandoz Laboratories. He accidentally discovered its psychoactive properties in 1943. His intentional self-experiment — cycling home under its effects — became known as "Bicycle Day." Read more in our profile of Albert Hofmann.

LSD is a potent agonist at serotonin receptors, particularly the 5-HT2A receptor. It is active at microgram doses — far smaller than any other psychedelic. Effects last eight to twelve hours. They include profound changes in perception, thought, emotion, and sense of self. Today, research into LSD-assisted therapy is resuming with early promise for anxiety, addiction, and cluster headaches.

LSD Analogues: 1P-LSD, 1cP-LSD, and the Grey Market

Because LSD itself remains illegal in most countries, a series of synthetic analogues has appeared on the grey market. These include 1P-LSD, 1cP-LSD, 1V-LSD, 1D-LSD, and — as of 2025 — 1S-LSD. Each time authorities ban one analogue, chemists produce the next variant. Germany alone has gone through five successive LSD analogues since 2019.

These substances act as prodrugs of LSD — meaning the body converts them into LSD after ingestion. They produce similar effects. However, the crucial difference: none of them have undergone formal human safety testing. No clinical trials exist. Long-term risks remain unknown. They are often sold as "research chemicals" or liquid drops ("druppels") on blotter paper.

MDMA: The Empathogen

MDMA (3,4-methylenedioxymethamphetamine) is technically classified as an empathogen rather than a classic psychedelic. However, its profound effects on consciousness and its growing therapeutic applications place it firmly in the synthetic psychedelics conversation.

MDMA was first synthesised in 1912, then rediscovered by Alexander Shulgin in the 1970s. Shulgin used his standard methodology: careful self-experimentation first, then sharing with therapists and his research group. He recognised its remarkable ability to dissolve emotional defences and enable honest communication. It entered club culture as "Ecstasy" in the 1980s and was banned by the mid-1980s.

Research has now resumed. Phase 3 clinical trials for MDMA-assisted PTSD therapy showed that over 70% of participants no longer met PTSD criteria after treatment. However, the FDA rejected Lykos Therapeutics' application in August 2024, requesting an additional study. For more, see our post on psychedelics and mental health treatment.

Synthetic Cathinones: 4-MMC, 3-MMC, and the Replacement Cycle

This is where synthetic psychedelics territory meets something far more dangerous. Synthetic cathinones — often misleadingly sold as "bath salts" or "plant food" — are stimulant drugs derived from cathinone, the active substance in the khat plant. The most well-known is mephedrone (4-MMC), which swept through Europe starting around 2009.

Mephedrone produces euphoria, empathy, and stimulation. Some users compare it to a rough combination of MDMA and cocaine. However, its safety profile is dramatically worse. Between 2009 and 2011, the UK documented 128 deaths associated with mephedrone use. Of 62 assessed cases, 26 died from acute toxicity and 18 from self-destructive behaviour.

When governments banned 4-MMC, 3-MMC appeared as a replacement. When 3-MMC was banned in the Netherlands, 2-MMC emerged as its replacement. Data from drug-checking services in 2024 showed that half of all samples sold as 3-MMC actually contained 2-MMC instead. In January 2026, the EU formally controlled three new synthetic cathinones: 2-MMC, 4-BMC, and NEP.

Psilocybin Analogues and "Paddo Druppels"

Another category of synthetic psychedelics gaining attention is psilocybin analogues — particularly 4-AcO-DMT (also known as "psilacetin"). This substance was first explored by Shulgin and later proposed by researcher David Nichols as a potential psilocybin prodrug for scientific research. It converts to psilocin in the body, producing effects similar to magic mushrooms.

4-AcO-DMT and related compounds (4-AcO-MET, 4-HO-MET) are sometimes sold as liquid drops — "paddo druppels" in Dutch — or as powder marketed as a research chemical. Because they mimic psilocybin effects, some people assume they are equally safe. However, research confirms that "almost nothing is known about their pharmacological effects" beyond basic receptor activity.

The appeal is clear: liquid drops offer precise dosing and discretion. However, the risk is equally clear. Unlike natural psilocybin from magic truffles, these synthetic analogues lack the safety data that decades of human use and clinical research provide. You simply do not know what you are putting in your body with the same certainty.

2C-B: Shulgin's Phenethylamine

2C-B (4-bromo-2,5-dimethoxyphenethylamine) is a synthetic psychedelic that Shulgin developed and documented in PiHKAL. It belongs to the phenethylamine class — a different chemical family from tryptamines like psilocybin. Effects are more sensory and less cognitively intense than LSD. Experiences typically last four to six hours.

2C-B was briefly used in therapeutic contexts in Europe before prohibition. Shulgin catalogued it alongside hundreds of other compounds. His work forms the foundation for much of what modern pharmaceutical companies now research. The key difference: Shulgin tested these substances himself. He documented the effects meticulously. Today's grey-market derivatives often have no such record.

Ketamine: The Legal Antidepressant

Ketamine occupies a unique position among synthetic psychedelics: it is legal, widely available, and already treating depression in clinics worldwide. Developed in the 1960s as a dissociative anaesthetic, it has been used in surgery and emergency medicine ever since.

At sub-anaesthetic doses, ketamine produces dissociative psychedelic effects — detachment from the body, rapid mood shifts, and altered perception. Its antidepressant effects appear within hours, compared to weeks for conventional drugs. Esketamine — a ketamine derivative — holds FDA approval as a nasal spray for treatment-resistant depression.

Ketamine-assisted therapy is now available at licensed clinics in many countries. For more on how this fits the broader picture, see our post on psychedelics and mental health treatment.

Shulgin vs. the Grey Market: A Critical Contrast

Here is why Shulgin's legacy matters so much to the conversation about synthetic psychedelics today. Shulgin created hundreds of novel compounds. Many were genuinely dangerous in the wrong hands. However, his process had a fundamental integrity that the modern grey market completely lacks:

Compare this to the current reality. Underground labs produce novel compounds. No one tests them on humans first. No dosing data exists. No duration data exists. No interaction data exists. These substances go directly from synthesis to sale — often labelled "not for human consumption" as a legal fiction. Consumers become the unwitting test subjects.

The European Drug Report 2025 reported that roughly 7,500 drug-related deaths occurred in the EU in 2023 alone. Novel psychoactive substances play an increasingly significant role in these numbers.

Natural vs. Synthetic: Does It Matter?

A common question: are synthetic psychedelics fundamentally different from natural ones? At the molecular level, not necessarily. Synthetic psilocybin is chemically identical to psilocybin from mushrooms. The effects are the same.

However, natural substances contain multiple compounds that may interact — sometimes called the "entourage effect." Consuming magic mushrooms means consuming psilocybin, psilocin, baeocystin, and other compounds together. Whether this mixture produces effects different from pure psilocybin is an active area of research.

There is also a cultural dimension. Many people find meaning in the plant or fungal origin of psychedelic medicines. For others, the reliability of a synthesised compound is preferable. Neither position is inherently right. For a broader overview of natural substances, see our guide to the most common types of psychedelics.

Harm Reduction and Testing

If you encounter synthetic psychedelics — whether well-known or novel — harm reduction can save your life:

For more on preparing safely, our guide on set and setting covers the essentials. Also read our integration guide for what to do afterward.

The Regulatory Picture in 2026

The regulatory landscape for synthetic psychedelics shifts rapidly. MDMA-assisted therapy is under review in multiple countries. Ketamine is already legal and available for depression treatment. LSD remains tightly controlled, though research programmes are active.

On the grey-market side, regulators are playing catch-up. Germany has banned five successive LSD analogues since 2019 — each time, a new one appears within months. The EU controlled three new cathinones in January 2026. The EUDA continuously monitors new substances, but the pace of synthesis outstrips the pace of regulation.

The direction for well-studied synthetic psychedelics is toward legitimacy. The direction for untested research chemicals is toward harm. Knowing which category a substance falls into is essential.